Claim being checked · Version 1 · Reviewed
“Tesamorelin is an approved general weight-loss drug.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Misleading. This statement leaves out a limit that changes its meaning.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for Tesamorelin.
01 · Answer
Misleading
The label specifically says it is not indicated for weight-loss management.
- What kind of evidence this is
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- What this answer covers
- The current Egrifta SV and Egrifta WR labels. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Approval and status. Whether a specific product has an approval or another official status.
02 · Sources
Read the sources behind this answer
01EGRIFTA SV (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the corrective verdict02EGRIFTA WR (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the corrective verdict
Supports the corrective verdict02EGRIFTA WR (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the corrective verdict
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.